• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

携带BRCA1基因突变的患者在接受预防性手术时以及其他良性和恶性妇科疾病患者的血清HE4水平

HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.

作者信息

Chudecka-Głaz Anita, Cymbaluk-Płoska Aneta, Strojna Aleksandra, Menkiszak Janusz

机构信息

Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.

出版信息

Dis Markers. 2017;2017:9792756. doi: 10.1155/2017/9792756. Epub 2017 Jan 15.

DOI:10.1155/2017/9792756
PMID:28182133
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5274692/
Abstract

. We assess the behavior of serum concentrations of HE4 marker in female carriers of BRCA1 and assess the diagnostic usefulness of HE4 in ovarian and endometrial cancer. . A total of 619 women with BRCA1 gene mutation, ovarian, endometrial, metastatic, other gynecological cancers, or benign gynecological diseases were included. Intergroup comparative analyses were carried out, the BRCA1 gene carriers subgroup was subjected to detailed analysis, and ROC curves were determined for the assessment of diagnostic usefulness of HE4 in ovarian and endometrial cancer. . Statistically lower serum HE4 and CA 125 levels were observed in BRCA1 gene mutation premenopausal carriers. Occult ovarian/fallopian tube cancer was found 3.6%. Each of those patients was characterized by slightly elevated levels of either CA 125 (63.9 and 39.4 U/mL) or HE4 (79 pmol/L). The ROC-AUC curves were 0.892 and 0.894 for diagnostic usefulness of ovarian cancer and 0.865 for differentiation of endometrial cancer from endometrial polyps. . Patients with BRCA1 gene mutations have relatively low serum HE4 levels. Even the slightest elevation in HE4 or CA 125 levels in female BRCA1 carriers undergoing prophylactic surgery should significantly increase oncological alertness. The HE4 marker is valuable in ovarian and uterine cancer diagnosis.

摘要

我们评估了BRCA1女性携带者血清中HE4标志物的水平，并评估了HE4在卵巢癌和子宫内膜癌中的诊断价值。纳入了619名携带BRCA1基因突变、患有卵巢癌、子宫内膜癌、转移性癌、其他妇科癌症或良性妇科疾病的女性。进行了组间比较分析，对BRCA1基因携带者亚组进行了详细分析，并绘制了ROC曲线以评估HE4在卵巢癌和子宫内膜癌中的诊断价值。在携带BRCA1基因突变的绝经前携带者中，观察到血清HE4和CA 125水平在统计学上较低。隐匿性卵巢/输卵管癌的发现率为3.6%。这些患者中的每一位的特征都是CA 125（63.9和39.4 U/mL）或HE4（79 pmol/L）水平略有升高。卵巢癌诊断的ROC-AUC曲线为0.892和0.894，子宫内膜癌与子宫内膜息肉鉴别的ROC-AUC曲线为0.865。携带BRCA1基因突变的患者血清HE4水平相对较低。在接受预防性手术的BRCA1女性携带者中，即使HE4或CA 125水平有最轻微的升高，也应显著提高肿瘤学警惕性。HE4标志物在卵巢癌和子宫癌诊断中具有重要价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c14/5274692/07884f28b961/DM2017-9792756.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c14/5274692/b7adf11fa1ec/DM2017-9792756.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c14/5274692/07884f28b961/DM2017-9792756.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c14/5274692/b7adf11fa1ec/DM2017-9792756.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c14/5274692/07884f28b961/DM2017-9792756.002.jpg

相似文献

1
HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.携带BRCA1基因突变的患者在接受预防性手术时以及其他良性和恶性妇科疾病患者的血清HE4水平
Dis Markers. 2017;2017:9792756. doi: 10.1155/2017/9792756. Epub 2017 Jan 15.
2
[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].[血清人附睾分泌蛋白4及CA125检测在卵巢恶性肿瘤诊断中的价值]
Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6.
3
[Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma].血清人附睾分泌蛋白E4与CA125联合检测在子宫内膜癌诊断中的临床价值
Zhonghua Fu Chan Ke Za Zhi. 2012 Feb;47(2):125-8.
4
Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.比较人附睾蛋白 4 与癌抗原 125 作为恶性和非恶性疾病患者的肿瘤标志物。
Clin Chem. 2011 Nov;57(11):1534-44. doi: 10.1373/clinchem.2010.157073. Epub 2011 Sep 20.
5
Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.开发一种多标志物检测方法用于鉴别诊断良恶性盆腔包块。
Clin Chim Acta. 2015 Feb 2;440:57-63. doi: 10.1016/j.cca.2014.11.013. Epub 2014 Nov 15.
6
[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].人附睾蛋白4与CA125联合检测在卵巢恶性肿瘤患者中的诊断价值
Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3.
7
CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.在术前管理中被诊断为子宫内膜癌的捷克女性人群中 CA125 和 HE4 水平。
Anticancer Res. 2014 Jan;34(1):327-31.
8
HE4 and ROMA index in Czech postmenopausal women.捷克绝经后女性的 HE4 和 ROMA 指数。
Anticancer Res. 2012 Sep;32(9):4137-40.
9
Value of serum human epididymis secretory protein 4 as a marker for differential diagnosis of malignant and benign gynecological diseases of patients in southern China.血清人附睾分泌蛋白4作为中国南方患者妇科良恶性疾病鉴别诊断标志物的价值
Clin Chim Acta. 2016 Aug 1;459:170-176. doi: 10.1016/j.cca.2016.06.010. Epub 2016 Jun 11.
10
Increased human epididymis protein 4 in benign gynecological diseases complicated with chronic renal insufficiency patients.良性妇科疾病合并慢性肾功能不全患者中人类附睾蛋白4升高。
Genet Mol Res. 2015 Mar 27;14(1):2156-61. doi: 10.4238/2015.March.27.2.

引用本文的文献

1
The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the Mutations.预防性附件切除术对携带突变的女性生活质量和社会心理功能的影响。
Int J Environ Res Public Health. 2019 Dec 9;16(24):4995. doi: 10.3390/ijerph16244995.
2
Usefulness of HE4 protein in differentiation of pelvic masses in woman.HE4蛋白在女性盆腔肿块鉴别诊断中的应用价值。
Prz Menopauzalny. 2019 Apr;18(1):27-32. doi: 10.5114/pm.2019.84154. Epub 2019 Apr 9.
3
Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.

本文引用的文献

1
Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.评估人附睾蛋白4（HE4）和卵巢恶性肿瘤风险算法（ROMA）作为日本女性I型和II型上皮性卵巢癌诊断工具的价值。
Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.
2
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.降低风险的输卵管卵巢切除术的病理结果：妇科肿瘤学组试验GOG-0199的初步结果
J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8.
3
中国卵巢癌患者血清肿瘤标志物与 BRCA1/2 种系突变的综合分析。
Mol Genet Genomic Med. 2019 Jun;7(6):e672. doi: 10.1002/mgg3.672. Epub 2019 Apr 10.
4
Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?波兰女性附件肿瘤术前鉴别中，卵巢恶性肿瘤算法是否比 HE4 和 CA125 提供更好的诊断性能？
Dis Markers. 2018 Apr 10;2018:5289804. doi: 10.1155/2018/5289804. eCollection 2018.
5
Determination of the Reference Values of the Tumor Marker HE4 in Female Population of Canton Sarajevo.萨拉热窝州女性人群中肿瘤标志物人附睾蛋白4参考值的测定
Mater Sociomed. 2018 Mar;30(1):15-19. doi: 10.5455/msm.2018.30.15-19.
6
Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.用于检测BRCA1突变携带者卵巢癌的诊断标志物。
PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017.
Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
BRCA1 或 BRCA2 基因突变女性行卵巢切除术对癌症发病率和死亡率的影响。
J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.
4
HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.HE4 转录和剪接变体在子宫内膜癌中的特异性表达及其与患者生存的相关性。
Int J Mol Sci. 2013 Nov 18;14(11):22655-77. doi: 10.3390/ijms141122655.
5
HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.人附睾蛋白 4 在原发性卵巢癌复发患者血浆中的表达与手术结果和总生存期相关。
Ann Surg Oncol. 2014 Mar;21(3):955-62. doi: 10.1245/s10434-013-3347-1. Epub 2013 Nov 12.
6
Serum HE4 as a prognostic marker in endometrial cancer--a population based study.血清 HE4 作为子宫内膜癌的预后标志物——一项基于人群的研究。
Gynecol Oncol. 2014 Jan;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036. Epub 2013 Nov 6.
7
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.HE4 在评估上皮性卵巢癌和子宫内膜癌中的新兴作用。
Oncology (Williston Park). 2013 Jun;27(6):548-56.
8
Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.血清人附睾蛋白 4 检测在卵巢癌诊断中的临床价值：一项荟萃分析。
Onco Targets Ther. 2013 Jul 23;6:957-66. doi: 10.2147/OTT.S45681. Print 2013.
9
Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis.筛查无症状女性卵巢癌的风险和获益：系统评价和荟萃分析。
Gynecol Oncol. 2013 Sep;130(3):674-81. doi: 10.1016/j.ygyno.2013.06.029. Epub 2013 Jun 30.
10
The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.人附睾蛋白4和血清淀粉样蛋白A在早期子宫内膜癌患者中的诊断作用
Tumour Biol. 2013 Oct;34(5):2645-50. doi: 10.1007/s13277-013-0814-z. Epub 2013 May 3.